{"id":390416,"date":"2019-05-22T00:00:00","date_gmt":"2019-05-22T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrcv0005-2019-biopharma-pulmonary-hypertension-current-treatment-physician-insights-us-2019\/"},"modified":"2026-04-30T11:24:38","modified_gmt":"2026-04-30T11:24:38","slug":"cutrcv0005-2019-biopharma-pulmonary-hypertension-current-treatment-physician-insights-us-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrcv0005-2019-biopharma-pulmonary-hypertension-current-treatment-physician-insights-us-2019\/","title":{"rendered":"Pulmonary Hypertension | Current Treatment: Physician Insights | US | 2019"},"content":{"rendered":"<p>Pulmonary hypertension (PH) is a rare and life-threatening disorder marked by considerable morbidity and mortality. Off-label drug use is widespread, with approved drugs available only for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) patients. In PAH patients, phosphodiesterase type 5 (PDE-5) inhibitors and endothelin receptor antagonists (ERAs) are most commonly prescribed as first-line treatment, with the more-efficacious prostacyclin therapies used in later lines. Branded therapies dominate the PAH treatment algorithm, and combination therapy is common. Adempas is the only approved therapy for CTEPH patients. PH is a highly lucrative market despite the relatively small patient population.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What is the current patient share of branded therapies such as United Therapeutics&#8217; Orenitram and Remodulin, Actelion\u2019s Opsumit, and Bayer\u2019s Adempas?<\/li>\n<li>What effect has the launch of Actelion\u2019s Uptravi had on treatment decisions?<\/li>\n<li>What are the anticipated changes in prescribing patterns over the next 12 months?<\/li>\n<li>How are specialists utilizing PAH therapies for the treatment of PH WHO Groups 2-5?<\/li>\n<li>What are U.S. specialists\u2019 attitudes and perceptions regarding diagnosis and treatment of PH?<\/li>\n<li>What are the drivers and constraints determining prescribing practices for PH?<\/li>\n<\/ul>\n<p><strong>Scope<\/strong><\/p>\n<ul>\n<li>Geography:\u00a0United States<\/li>\n<li>Primary Research: Survey of 101\u00a0U.S. cardiologists \/\u00a0pulmonologists<\/li>\n<li>Key Drugs Covered:\u00a0Uptravi, Opsumit, Remodulin, Tyvaso, Orenitram, Adempas, sildenafil, tadalafil, iloprost, epoprostenol<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390416","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hypertension","biopharma-therapy-areas-pulmonary-hypertension","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390416","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390416\/revisions"}],"predecessor-version":[{"id":393541,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390416\/revisions\/393541"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390416"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}